Balyasny Asset Management L.P. Has $9.18 Million Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Balyasny Asset Management L.P. lifted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 6.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,187,102 shares of the biotechnology company’s stock after buying an additional 66,993 shares during the period. Balyasny Asset Management L.P. owned about 2.40% of REGENXBIO worth $9,176,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of RGNX. Barclays PLC grew its holdings in shares of REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock worth $1,217,000 after purchasing an additional 67,948 shares during the last quarter. GAMMA Investing LLC boosted its position in REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the period. Assenagon Asset Management S.A. grew its holdings in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after acquiring an additional 296,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its position in REGENXBIO by 8.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock valued at $1,273,000 after acquiring an additional 13,014 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of REGENXBIO during the fourth quarter valued at $1,062,000. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Stock Up 5.2 %

RGNX opened at $7.52 on Friday. The business’s fifty day simple moving average is $7.32 and its 200 day simple moving average is $8.02. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $16.85. The stock has a market cap of $376.88 million, a PE ratio of -1.50 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. As a group, equities analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on RGNX shares. The Goldman Sachs Group reduced their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, April 17th. Morgan Stanley increased their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a research note on Tuesday, January 21st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.